loadpatents
Patent applications and USPTO patent grants for Osborne; David Wade.The latest application filed is for "corticosteroid compositions".
Patent | Date |
---|---|
Corticosteroid Compositions App 20190000977 - Lathrop; Robert W. ;   et al. | 2019-01-03 |
Corticosteroid compositions Grant 10,111,956 - Lathrop , et al. October 30, 2 | 2018-10-30 |
Corticosteroid Compositions App 20150209429 - Lathrop; Robert ;   et al. | 2015-07-30 |
Corticosteroid Compositions App 20140357607 - Lathrop; Robert ;   et al. | 2014-12-04 |
Azithromycin for treatment of skin disorders Grant 8,143,227 - Dow , et al. March 27, 2 | 2012-03-27 |
Azithromycin for the treatment of nodular acne App 20100216732 - Osborne; David Wade ;   et al. | 2010-08-26 |
Azithromycin for the treatment of nodular acne Grant 7,704,959 - Osborne , et al. April 27, 2 | 2010-04-27 |
Azithromycin for treatment of skin disorders App 20090062221 - Dow; Gordon Jay ;   et al. | 2009-03-05 |
Azithromycin for the treatment of nodular acne App 20080081790 - Osborne; David Wade ;   et al. | 2008-04-03 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.